SCHEMBL8676830

SCHEMBL8676830

Cc1cc(Cl)ccc1P(c1ccc(Cl)cc1C)c1ccc(Cl)cc1C

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.44
NOX1 Q9Y5S8 1/20 0.38
CYP2A6 P11509 2/20 0.38
POLB P06746 2/20 0.36
GAA P10253 1/20 0.36
NOTUM Q6P988 1/20 0.36
TP53 P04637 2/20 0.36
FLT1 P17948 1/20 0.36
FLT4 P35916 1/20 0.36
KDR P35968 1/20 0.36
RAPGEF4 Q8WZA2 2/20 0.35
LMNA P02545 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TSHR P16473 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2159642 0.83 CYP3A4 (0.41) CYP3A4CYP2A6GAAFLT1FLT4
SCHEMBL15748687 0.80 CYP3A4 (0.50) CYP3A4NOX1CYP2A6POLBGAA
SCHEMBL381504 0.74 TDP1 (0.46) CYP3A4CYP2A6TP53RAPGEF4SMN1; SMN2
SCHEMBL31556280 0.73
SCHEMBL91997 0.73
Bromide SCHEMBL11384376 0.72 TDP1 (0.44) CYP3A4CYP2A6TP53RAPGEF4SMN1; SMN2
SCHEMBL31325517 0.72 TDP1 (0.44) CYP3A4CYP2A6TP53RAPGEF4SMN1; SMN2
SCHEMBL9294360 0.72 TDP1 (0.44) CYP3A4CYP2A6TP53RAPGEF4SMN1; SMN2
SCHEMBL167920 0.70
SCHEMBL29719717 0.70 NOTUM (0.53) CYP3A4NOX1CYP2A6POLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10370393-B2 Stereoretentive cross-coupling of boronic acids THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2019-08-06 US disclosed
US-20180305381-A1 STEREORETENTIVE CROSS-COUPLING OF BORONIC ACIDS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2018-10-25 US disclosed
WO-2012116977-A1 PROCESS FOR THE PREPARATION OF 3-METHYLENE-γ-BUTYROLACTONE DSM IP ASSETS B.V. (NL) 2012-09-07 WO disclosed
EP-0841332-A1 Method for preparing alpha-methylene-beta-methyl-gamma-butyrolactone and 4-hydroxy-butyric aldehyde as well as 2-hydroxa-3-methylene-4-methyltetrahydrofuran being valuable intermediates Degussa Aktiengesellschaft (DE) 1998-05-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10370393-B2 Stereoretentive cross-coupling of boronic acids NBAS, CNKSR1, REL CYP3A4 3574/4885NOX1 1243/4885CYP2A6 672/4885
US-20180305381-A1 STEREORETENTIVE CROSS-COUPLING OF BORONIC ACIDS TACR1, TACR2, BRS3 CYP3A4 2812/4885NOX1 4089/4885CYP2A6 1633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.